NXTC SEC Filings: 8-K, 10-Q, S-3 & 424B – NextCure

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 1, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NextCure Announces Departure of Chief Medical Officer Dr. Udayan Guha Ahead of Merger

Oct 30, 2026

8-K

NextCure Seeks Court Validation of 2025 Reverse Stock Split Amid Merger Uncertainty

Sep 25, 2026

8-K

NextCure, Inc. Terminates Lease Agreement for Beltsville, Maryland Facility

Sep 3, 2026

8-K

NextCure Reports Q2 2026 Results and Provides Update on Proposed Merger with Avere Therapeutics

Aug 6, 2026

8-K

Merger Announced to Advance Oral IL-23 Therapy with $320 Million Investment, Led by Experienced Biotech Executives

Jul 14, 2026

8-K

NextCure, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 25, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

OFFERING - OTHER | Offering amount: $820,000,000

Nov 6, 2026

425

Form 425 - Prospectuses and communications, business combinations

Sep 25, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 10, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 4, 2026

425

Form 425 - Prospectuses and communications, business combinations

Jul 16, 2026

425

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

Jul 14, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Nov 5, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 30, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 30, 2026

S-4

Andrew Cheng Consents to Serve as Director for NextCure Post-Merger

Aug 18, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Dec 9, 2025

S-3

SHARE RESALE REGISTRATION

Nov 26, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 19, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 19, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

Ownerships

TYPE

HEADLINE

FILED AT

NEWSchneeberger Daniel (Reporting)

Nov 9, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Nov 5, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 30, 2026

Schneeberger Daniel (Reporting)

Oct 27, 2026

SCHEDULE 13G

JP Sailing Capital Ltd (Filed by)

Oct 20, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 30, 2026

Other

TYPE

HEADLINE

FILED AT

NextCure, Inc. NXTC · SEC Filings